Rubius Therapeutics (DB:5RT) - Hisse Senedi Fiyatı, Haberler ve Analizler

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

5RT Stoklara Genel Bakış

Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. Daha fazla detay

5RT temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Risk Analizi

Anlamlı bir piyasa değeri yok ( €2M )

Hisse senetleri oldukça likit değildir

Geliri 1 milyon ABD dolarından az ( $0 )

Kazançlar son 5 yılda yılda 21.3% oranında azaldı

+ 1 daha fazla risk

Rubius Therapeutics, Inc. Rakipler

Epigenomics

XTRA:ECX

€616.0k

bioXXmed

XTRA:T5O

€1.4m

co.don

XTRA:CNW

€6.5m

Deutsche Biotech Innovativ

DUSE:DBI

€1.1m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Rubius Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.013
52 Haftanın En Yüksek Seviyesi	US$1.40
52 Haftanın En Düşük Seviyesi	US$0.013
Beta	2.39
11 Aylık Değişim	0%
3 Aylık Değişim	-23.53%
1 Yıllık Değişim	n/a
33 Yıllık Değişim	-99.75%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-99.94%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	5RT	DE Biotechs	DE Pazar
7D	0%	-0.7%	-0.02%
1Y	n/a	-17.2%	8.2%

Getiri vs. Endüstri: 5RT un German Biotechs sektörüne göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Getiri vs Piyasa: 5RT un German Piyasasına göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Fiyat Oynaklığı

Is 5RT's price volatile compared to industry and market?
5RT volatility
5RT Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 5RT hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 5RT 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2013	6	Craig Jalbert	www.rubiustx.com

Rubius Therapeutics, Inc. Temel Bilgiler Özeti

Rubius Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
5RT temel i̇stati̇sti̇kler
Piyasa değeri	€1.73m
Kazançlar(TTM)	-€167.23m
Gelir(TTM)	n/a

0.0x

P/S Oranı

0.0x

F/K Oranı

5RT aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
5RT gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$179.67m
Kazançlar	-US$179.67m

Son Raporlanan Kazançlar

Dec 31, 2022

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.99
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

5RT uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

This company listing is no longer active

5RT Stoklara Genel Bakış

Risk Analizi

Rubius Therapeutics, Inc. Rakipler

XTRA:ECX

€616.0k

XTRA:T5O

€1.4m

XTRA:CNW

€6.5m

DUSE:DBI

€1.1m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Less than half of directors are independent

Rubius Therapeutics Receives Non-Compliance Letter from Nasdaq

High number of new and inexperienced directors

Rubius Therapeutics, Inc. Announces Leadership Changes

Rubius Therapeutics, Inc. Announces Resignation of David Epstein as a Member of the Board

Rubius Therapeutics Announces Strategic Update

Recent updates

Less than half of directors are independent

Rubius Therapeutics Receives Non-Compliance Letter from Nasdaq

High number of new and inexperienced directors

Rubius Therapeutics, Inc. Announces Leadership Changes

Rubius Therapeutics, Inc. Announces Resignation of David Epstein as a Member of the Board

Rubius Therapeutics Announces Strategic Update

Rubius Therapeutics, Inc. Announces Resignation of Natalie Holles as Member of the Board of Directors

Rubius Therapeutics Receives Non-Compliance Letter from Nasdaq

Rubius Therapeutics, Inc. Appoints Susanne Schaffert to Its Board of Directors

Rubius Therapeutics, Inc.(NasdaqGS:RUBY) dropped from Russell 2000 Growth Index

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

Rubius Therapeutics, Inc. Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability

Rubius Therapeutics, Inc., Annual General Meeting, May 12, 2022

Rubius Therapeutics, Inc. to Report Q4, 2021 Results on Feb 25, 2022

Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors

Rubius Therapeutics to Highlight the Power of RED PLATFORM®, Significant Advances Across Red Cell Therapeutic Oncology Pipeline and New Type 1 Diabetes Program at Platform and Pipeline Day

Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy

Rubius Therapeutics, Inc.(NasdaqGS:RUBY) dropped from Russell 3000E Value Index

Rubius Therapeutics, Inc. Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® in Ongoing Phase 1/2 Clinical Trial for Treatment of Advanced Solid Tumors

Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting

Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature Communications

Rubius Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity

Rubius Therapeutics Announces Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240

New 90-day high: €12.50

Rubius Therapeutics, Inc. to Report Q4, 2020 Results on Feb 23, 2021

New 90-day high: €8.10

Rubius Therapeutics, Inc. Provides an Operational Update

New 90-day high: €7.90

New 90-day high: €4.92

Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic Clinical Oncology Program, Rtx-240, at the Society for Immunotherapy of Cancer’s Annual Meeting

Rubius Therapeutics, Inc. Announces Dosing of First Patient with Relapsed/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1/2 Clinical Trial of RTX-240

Rubius Therapeutics, Inc. to Report Q3, 2020 Results on Nov 09, 2020

New 90-day low: €3.84

Rubius Therapeutics, Inc. Appoints Jose Carmona as Principal Financial Officer, Principal Accounting Officer and Treasurer Effective as of October 1, 2020

New 90-day low: €3.92

New 90-day low - €4.00

Rubius Therapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020

New 90-day low - €4.92

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Rubius Therapeutics, Inc. Temel Bilgiler Özeti

0.0x

0.0x

Kazanç ve Gelir